2014年9月18日（星期四）下午

Thursday Afternoon, Sept.18^th, 2014

IASLC-CSCO Joint Symposium

Venue: 1D Meeting Room, 1st Floor, Xiamen International Conference Center

Co-Chairs: Tony Mok (CSCO) 莫树锦

          Fred R. Hirsch (IASLC)

Keynote Speech

14:30~14:50  First line TKI: where we are and where we should be

            Tony Mok 莫树锦   Chinese University of Hong Kong, China

14:50~14:55  Q&A

14:55~15:15  Mono-clonal antibody against EGFR for management of advanced stage NSCLC

            Fred R. Hirsch   University of Colorado Cancer Center, USA

15:15~15:20  Q&A

15:20~15:40  ALK TKI resistance: Mechanism and potential solution

            Robert C. Doebele   University of Colorado, USA

15:40~15:45  Q&A

15:45~16:05  EGFR TKI resistance: Mechanism and potential solution

            Pasi A. Jänne   Dana Farber Cancer Institute, USA

16:05~16:10  Q&A

16:10~16:30  Novel targets and novel agents

            Cai-Cun Zhou 周彩存   Shanghai Pulmonary Hospital, China

16:30~16:35  Q&A

Oral Presentations

16:35~16:45  Tumorigenic potential of circulating tumor cells in pulmonary venous blood from Non-Small Cell Lung patients in xenograft model

            Chao Lv 吕  超   Beijing Cancer Hospital, China

16:45~16:55  Clinicopathological characteristics and outcome of 59 Chinese patients with adenosquamous lung carcinoma

            Ye Guo 郭  晔   1st Affiliated Hospital of Jilin University, China

16:55~17:05  Safety and clinical activity of pembrolizumab (pembro, MK-3475) as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)

            Naiyer A. Rizvi   Memorial Sloan-Kettering Cancer Center (MSKCC), USA

17:05~17:15  Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts) with non-small cell lung cancer (NSCLC)

            Naiyer A. Rizvi   Memorial Sloan-Kettering Cancer Center (MSKCC), USA

17:15~17:25  Abstract Discussion

            Yun Fan 范 云   Zhejiang Provincial Cancer Hospital, China

17:25~17:35  Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1615 Global Phase III trial): Outcomes in Chinese patients

            Cai-Cun Zhou周彩存   Shanghai Pulmonary Hospital, China

17:35~17:45  Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-small cell lung cancer (NSCLC) in East Asian patients

            James Chih-Hsin Yang 杨志新   National Taiwan University Hospital, China

17:45~17:55  Drug exposure and safety of Pemetrexed/Platinum versus other Platinum-based doublets as first-line treatment in East-Asian patients with advanced non-squamous non-small cell lung cancer

            Shun Lu 陆  舜   Shanghai Chest Hospital, China

17:55~18:00  Abstract Discussion

            Xiao-Qing Liu 刘晓晴   No.307 Hospital, China